AUTHOR=Li Jian-Jun , Zhao Shui-Ping , Zhao Dong , Lu Guo-Ping , Peng Dao-Quan , Liu Jing , Chen Zhen-Yue , Guo Yuan-Lin , Wu Na-Qiong , Yan Sheng-Kai , Wang Zeng-Wu , Gao Run-Lin , Chen Hong , Chen Zhenyue , Cheng Xiang , Chen Yundai , Chen Zhenyue , Dong Yugang , Dou Kefei , Gao Runlin , Gu Dongfeng , Ge Junbo , Gao Wei , Guo Yifang , Guo Yuanlin , Gao Runlin , Guo Yuanlin , Gao Ying , Huo Yong , Han Suling , Hu Dayi , Jia Weiping , Ji Linong , Liu Meilin , Li Jianjun , Lu Guoping , Li Yong , Li Jing , Li Xiaoying , Li Guangwei , Liao Yuhua , Lu Guoping , Liu Jing , Li Jianjun , Liang Chun , Ma Changsheng , Ma Yitong , Ma Liyuan , Ning Guang , Peng Daoquan , Peng Daoquan , Sun Yihong , Shi Xubo , Tang Yida , Wang Zengwu , Wang Zengwu , Wu Naqiong , Wu Yangfeng , Wang Zengwu , Wu Naqiong , Wang Chengbin , Wang Yongjun , Xiang Wei , Yan Shengkai , Yan Xiaowei , Yan Shengkai , Yuan Zuyi , Yu Bo , Ye Ping , Zhu Dalong , Zhang Yun , Zhao Jiajun , Zhao Dong , Zhao Shuiping , Zou Dajin , Zhang Jian , Zhang Ruiyan , Zhou Zhou , Zhao Wenhua , Zhu Ye , Zhu Zhiming , Zeng Zhengpei , Zhan Siyan , Zhao Dong , Zhao Shuiping TITLE=2023 Chinese guideline for lipid management JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1190934 DOI=10.3389/fphar.2023.1190934 ISSN=1663-9812 ABSTRACT=

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death among urban and rural residents in China, and elevated low-density lipoprotein cholesterol (LDL-C) is a risk factor for ASCVD. Considering the increasing burden of ASCVD, lipid management is of the utmost importance. In recent years, research on blood lipids has made breakthroughs around the world, hence a revision of Chinese guideline for lipid management is imperative, especially since the target lipid levels in the general population vary in respect to the risk of ASCVD. The level of LDL-C, which can be regarded as appropriate in a population without frisk factors, can be considered abnormal in people at high risk of developing ASCVD. As a result, the “Guidelines for the prevention and treatment of dyslipidemia" were adapted into the “Chinese guideline for Lipid Management" (henceforth referred to as the new guidelines) by an Experts’ committee after careful deliberation. The new guidelines still recommend LDL-C as the primary target for lipid control, with cardiovascular disease (CVD) risk stratification to determine its target value. These guidelines recommend that moderate intensity statin therapy in adjunct with a heart-healthy lifestyle, be used as an initial line of treatment, followed by cholesterol absorption inhibitors or/and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, as necessary. The new guidelines provide guidance for lipid management across various age groups, from children to the elderly. The aim of these guidelines is to comprehensively improve the management of lipids and promote the prevention and treatment of ASCVD by guiding clinical practice.